CVS, UnitedHealth, Cigna sue to block FTC case over insulin prices

CVS, UnitedHealth, Cigna sue to block FTC case over insulin prices


CVS Pharmacy logo is seen in Washington DC, United States on July 9, 2024.

Jakub Porzycki | Nurphoto | Getty Images

CVS Health, UnitedHealth Group and Cigna sued the Federal Trade Commission on Tuesday, claiming that the agency’s case against drug supply chain middlemen over high insulin prices in the U.S. is unconstitutional. 

The complaint, filed in the U.S. District Court for the Eastern District of Missouri, is the latest move in a bitter legal fight between the three largest pharmacy benefit managers, or PBMs, in the U.S. and the FTC.

The FTC in September sued CVS’s Caremark, Cigna’s Express Scripts and UnitedHealth’s Optum Rx in the agency’s administrative court, accusing those PBMs and other drug middlemen of using a “perverse” rebate system to boost their profits while inflating insulin costs for Americans. 

The FTC’s in-house administrative process initiates a proceeding before an administrative judge who would hear the case. FTC commissioners then vote on that opinion.

The Tuesday complaint argues that the FTC’s process violates the companies’ due process rights under the Fifth Amendment. The companies also allege that the FTC’s claims involve private rights that must be litigated in federal court rather than in the agency’s in-house administrative court. 

The companies called that process “fundamentally unfair,” noting that commissioners and an administrative law judge are “unconstitutionally insulated from removal by the President and thus are insulated from democratic accountability.” 

“This sweeping attempt to reshape an entire industry via law enforcement would never pass muster in a US district court,” the complaint said. 

In a statement Tuesday, FTC spokesperson Douglas Farrar said “it has become fashionable for corporate giants to argue that a 110-year-old federal agency is unconstitutional to distract from business practices that we allege, in the case of PBMS, harm sick patients by forcing them to pay huge sums for life saving medicine. It will not work.”

PBMs sit at the center of the drug supply chain in the U.S. They negotiate rebates with drug manufacturers on behalf of health plans, reimburse pharmacies for prescriptions and create lists of medications covered by insurance. 

The complaint comes a month after CVS, UnitedHealth Group and Cigna demanded FTC Chair Lina Khan and two other commissioners recuse themselves from the agency’s in-house suit. In separate motions, the companies argued that all three commissioners have an extensive track record of making public statements that indicate allegedly serious bias against the PBMs. 

Caremark, Express Scripts and Optum Rx are all owned by or connected to health insurers and collectively administer about 80% of the nation’s prescriptions, according to the FTC. 



Source

Home flippers see smallest profits since the Great Recession, real estate data firm says
Business

Home flippers see smallest profits since the Great Recession, real estate data firm says

A version of this article first appeared in the CNBC Property Play newsletter with Diana Olick. Property Play covers new and evolving opportunities for the real estate investor, from individuals to venture capitalists, private equity funds, family offices, institutional investors and large public companies. Sign up to receive future editions, straight to your inbox. Higher […]

Read More
More women are entering wealth management, but few are in advisory roles, study finds
Business

More women are entering wealth management, but few are in advisory roles, study finds

Contract, woman and advisor in office for signature, information or document for job application. Advice, client or human resource agent with paperwork for registration, opportunity or deal agreement Jacob Wackerhausen | Istock | Getty Images A version of this article first appeared in CNBC’s Inside Wealth newsletter with Robert Frank, a weekly guide to the […]

Read More
EV battery startup pivots to defense industry amid Iran war, weak electric vehicle market
Business

EV battery startup pivots to defense industry amid Iran war, weak electric vehicle market

Low-cost Unmanned Combat Attack System (LUCAS) drones are positioned on the tarmac at a base in the U.S. Central Command operating area. Source: U.S. CENTCOM An Arizona-based battery startup led by a former General Motors executive is moving from making products for all-electric vehicles to making products for the aerospace and defense industries amid the […]

Read More